1. Home
  2. BCDA vs YGMZ Comparison

BCDA vs YGMZ Comparison

Compare BCDA & YGMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • YGMZ
  • Stock Information
  • Founded
  • BCDA N/A
  • YGMZ 2002
  • Country
  • BCDA United States
  • YGMZ China
  • Employees
  • BCDA N/A
  • YGMZ N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • YGMZ Transportation Services
  • Sector
  • BCDA Health Care
  • YGMZ Consumer Discretionary
  • Exchange
  • BCDA Nasdaq
  • YGMZ Nasdaq
  • Market Cap
  • BCDA 7.9M
  • YGMZ 7.0M
  • IPO Year
  • BCDA N/A
  • YGMZ 2020
  • Fundamental
  • Price
  • BCDA $2.32
  • YGMZ $0.66
  • Analyst Decision
  • BCDA Strong Buy
  • YGMZ
  • Analyst Count
  • BCDA 1
  • YGMZ 0
  • Target Price
  • BCDA $25.00
  • YGMZ N/A
  • AVG Volume (30 Days)
  • BCDA 52.0K
  • YGMZ 57.6K
  • Earning Date
  • BCDA 03-26-2025
  • YGMZ 01-01-0001
  • Dividend Yield
  • BCDA N/A
  • YGMZ N/A
  • EPS Growth
  • BCDA N/A
  • YGMZ N/A
  • EPS
  • BCDA N/A
  • YGMZ N/A
  • Revenue
  • BCDA $71,000.00
  • YGMZ $55,805,416.00
  • Revenue This Year
  • BCDA N/A
  • YGMZ N/A
  • Revenue Next Year
  • BCDA N/A
  • YGMZ N/A
  • P/E Ratio
  • BCDA N/A
  • YGMZ N/A
  • Revenue Growth
  • BCDA N/A
  • YGMZ N/A
  • 52 Week Low
  • BCDA $1.63
  • YGMZ $0.64
  • 52 Week High
  • BCDA $8.85
  • YGMZ $6.24
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 49.50
  • YGMZ 40.85
  • Support Level
  • BCDA $2.12
  • YGMZ $0.64
  • Resistance Level
  • BCDA $2.73
  • YGMZ $0.75
  • Average True Range (ATR)
  • BCDA 0.23
  • YGMZ 0.07
  • MACD
  • BCDA 0.01
  • YGMZ 0.00
  • Stochastic Oscillator
  • BCDA 35.82
  • YGMZ 29.62

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About YGMZ MingZhu Logistics Holdings Limited

MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.

Share on Social Networks: